Connect with us:

Facebook Twitter RSS

Videos

Reasons to attend the EurocanPlatform translational research course 2015

Dr Wilfried Reichardt, University Medical Center Freiburg, Freiburg, Germany

Added: 06 Jan 2015

Dr Reichardt speaks to ecancer at the 2nd EurocanPlatform Translational Research Course, outlining his reasons for attending the EurocanPlatform translational research course.

He felt its broad overview of modern translational research and high-profile speakers were its main strengths.

Find out more about the EurocanPlatform project here

More video

'Conquer Fear' of disease recurrence
Comment: Niraparib for ovarian cancer
Post-translational modification (PTM) profiling – a novel tool for mapping the PTM landscape in cancer
EurocanPlatform 'Biomarkers, screening and prevention in cancer' Special Issue
Medical cancer prevention
Drug resistance mechanisms
Prediction of side-effects of anti-cancer drugs
The DNA damage response
From genotype to molecular phenotype by proteomics
Mouse models for complex aspects in human cancer
Functional characterisation of therapeutic targets through comparative pharmacology
Cancer systems biology
Cancer diagnosis and evaluation of treatment in the genomic era
Cancer Core Europe: where did it come from and what is its future?
Mouse tumour models in the EurocanPlatform project
Clinical epidemiology in the EurocanPlatform project
Therapeutic strategies in the EurocanPlatform project
Quality assessment, accreditation and metrics in the EurocanPlatform project
Biobanking in the EurocanPlatform project
The POSEIDON trial of the EurocanPlatform project
Education and training in the EurocanPlatform project
Highlights of the EurocanPlatform Project
Highlights of Cancer Prevention Europe
Cancer Core Europe: what has been achieved one year on?
Cancer Prevention Europe
Cancer Core Europe: one year on (full version)
The role of health economics in cancer outcomes research
Paediatric drug development and the importance of collaboration
Future research perspectives: the relationship between academia and industry
Cancer cell models for improved therapies
Biobanking biological materials and linkage to clinical information
The p-medicine project and personalised medicine
2nd EurocanPlatform translational research course is good for networking
Hormone receptor function in breast cancer therapy
Immunotherapy of cancer: recent progress and future challenges
Epigenome deregulation in cancer
Aims and successes of the 2nd EurocanPlatform project translational research course
The DNA damage response and cancer therapy
Biomarkers for early detection and risk of relapse in breast cancer
New approaches and new partnership models for biomarker based clinical research
Cancer Core Europe: Introduction
Cancer Core Europe: National Center for Tumor Diseases
Cancer Core Europe: Vall d'Hebron Institute of Oncology
Cancer Core Europe: Cancer Research UK Cambridge Institute
Cancer Core Europe: Karolinska Institute
Cancer Core Europe: Institut Gustave Roussy
Cancer Core Europe: Netherlands Cancer Institute
Cancer Core Europe: Questions and answers
E-hospital: Fully coordinated cancer care and research in Europe
Patient information needs in biomarkers and biobanking
Overview of the EurocanPlatform
Landmark cooperative projects in Portugal
Excellence in comprehensive cancer care
Manchester Cancer Services
Establishment of the EurocanPlatform
Evolution of the EurocanPlatform
Institute Jules Bordet and the OECI
Molecular stratification of breast cancer: reaching the clinic
Translational and tailored, but can we afford it?
Translational and tailored, but can we afford it?
Cost efficiency of targeted therapy
Society and money - the cancer conundrum
Translating cancer research to personalised treatment: Can it work?
The OECI and EurocanPlatform
Problems in the structure of clinical trials
Transfer of information through EurocanPlatform
Use of bio-banks in the EurocanPlatform
Progress of the EurocanPlatform, one year on
Innovation in molecular imaging
Advances in radiation oncology
EurocanPlatform and the exchange of information
Effects of lifestyle change in cancer patients
Benefits of open European research area
Improving educational events and courses
EurocanPlatform project update
Debate on the success of breast cancer screening programmes
Analysis of thirty years of clinical trial data
Cost of MRI screening for women with a family history of breast cancer
Effectiveness of breast cancer screening
Results from national breast cancer screening programme
Axillary dissection may be overtreatment in some breast cancer patients
Optimal treatment schedule for pomalidomide in multiple myeloma
Influence of age and BRCA status on contralateral breast cancer risk
Reduction of cancer burden across Africa
Preventing cervical cancer in sub-Saharan Africa
New trastuzumab combinations for HER2 positive breast cancer
Key procedures of molecular diagnosis
Metabolic imaging using magnetic resonance
Lifetime achievement award and future work
Toxicity and side effect prevention
Understanding tumour metastasis
Cellular pathways in lung cancer and the need for personalised medicine
Aspirin for the elderly to reduce cancer risk
Highlights from day one of the 5th International Workshop
Smaller, faster clinical trials
2011 St Gallen Consensus breast cancer recommendations
Review of prostate cancer at EMCC 2011
Radium 223 in the ALSYMPCA trial
Mechanisms of DNA damage processing in stem cells